Nathan H. Fowler MD

PubMed

• A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.
  Neha Akkad, Lei Feng, Jason R Westin, Fredrick B Hagemeister, Hun Ju Lee
  Blood Advances. 2025-09-09
• 1 citations
  Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.
  Ashwath Gurumurthi, Collin K Chin, Lei Feng, Nathan H Fowler, Paolo Strati
  Eclinicalmedicine. 2024-08-01
• 66 citations
  Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
  Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad
  Blood. 2024-04-25

Journal Articles

• Venetoclax, Bendamustine, and Rituximab in Patients with Relapsed or Refractory NHL: A Phase 1b Dose-Finding Study  
  N Fowler, E Reid, L J Nastoupil, Annals of Oncology

Abstracts/Posters

• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
  Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed p... 
  2019 ASCO Annual Meeting - 6/1/2019
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018